{"schema_version":"secwatch.filing_event.v1","accession":"0001534969-23-000091","form_type":"8-K","ticker":"SERA","cik":"0001534969","company_name":"SERA PROGNOSTICS, INC.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.233939+00:00","generated_at":"2026-06-11T22:01:34.730962+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sera Q2 revenue $123K, net loss $10.5M; appoints interim CEO and CFO","bullets":["Revenue $123,000 (Q2 2023) vs $78,000 (Q2 2022), up 58% YoY but still minimal.","Net loss $10.5M vs $11.5M; operating expenses $11.6M vs $11.8M.","Cash, equivalents, and securities $92.1M as of June 30, 2023.","Appointed Zhenya Lindgardt interim President/CEO and Austin Aerts interim CFO; headcount reductions in commercial team.","Engaged strategy firm to evaluate paths to enhance revenue at reduced cost for PreTRM Test commercialization."],"urls":{"canonical":"https://secwatch.observer/filing/0001534969-23-000091","json":"https://secwatch.observer/filing/0001534969-23-000091.json","markdown":"https://secwatch.observer/filing/0001534969-23-000091.md","text":"https://secwatch.observer/filing/0001534969-23-000091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534969/000153496923000091/0001534969-23-000091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534969/000153496923000091/sera-20230809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T22:01:34.730962+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"da88b636dede068aa0973535739dcc4976ed1ded","claim":"SERA PROGNOSTICS, INC. reported the second quarter ended June 30, 2023 results: revenue $123,000, net income $10.5 million.","evidence_excerpt":"our role as a leader in health diagnostics to improve the lives of women and babies through prenatal care.” Second Quarter 2023 Financial Results Second quarter 2023 revenue of $123,000 compared to $78,000 for the same period of 2022. Total operating expenses were $11.6 million, down from $11.8 million for the second quarter of 2022. Research and development","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534969/000153496923000091/0001534969-23-000091-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$123,000"},{"label":"Net income","value":"$10.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}